Active Ingredient History
Vinblastine is a Vinca alkaloid obtained from the Madagascar periwinkle plant. Vinca alkaloids were found out in the 1950's by Canadian scientists, Robert Noble and Charles Beer for the first time. Medicinal applications of this plant lead to the monitoring of these compounds for their hypoglycemic activity, which is of little importance compared to their cytotoxic effects. They have been used to treat diabetes, high blood pressure and the drugs have even been used as disinfectants. Nevertheless, the vinca alkaloids are so important for being cancer fighters. The mechanism of action of vinblastine sulfate has been related to the inhibition of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vinblastine is an antineoplastic agent used to treat Hodgkin's disease, non-Hodgkin's lymphomas, mycosis fungoides, cancer of the testis, Kaposi's sarcoma, Letterer-Siwe disease, as well as other cancers. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Histiocytosis, Langerhans-Cell (approved 1987)
Hodgkin Disease (approved 1987)
Lymphoma, Non-Hodgkin (approved 1987)
Mycosis Fungoides (approved 1987)
Sarcoma, Kaposi (approved 1987)
Testicular Neoplasms (approved 1987)
Acne Vulgaris (Phase 2)
Astrocytoma (Phase 3)
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 3)
Central Nervous System (Phase 1)
Central Nervous System Neoplasms (Phase 1)
Geriatrics (Phase 3)
Glioma (Phase 3)
Histiocytosis, Langerhans-Cell (Phase 3)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 4)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 3)
Leukemia, Myeloid, Acute (Phase 2)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 3)
Lymphocytosis (Phase 2)
Lymphoma (Phase 4)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 3)
Melanoma (Phase 3)
Mesothelioma, Malignant (Phase 2)
Mycoses (Phase 1)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 1)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuroblastoma (Phase 2)
Neurofibromatosis 1 (Phase 2)
Ovarian Neoplasms (Phase 3)
Precancerous Conditions (Phase 2)
Prostatic Neoplasms (Phase 3)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 2)
Sclerosis (Phase 2)
Skin Neoplasms (Phase 3)
Testicular Neoplasms (Phase 3)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
